Related Experiment Videos
[IMesenteric and mesocolic cystic lymphangiomas. Diagnostic and therapeutic management]
J Y Mabrut1, J P Grandjean, L Henry
1Service de chirurgie générale, digestive et de transplantation hépatique, hôpital de la Croix-Rousse, 103, Grande-rue-de-la-Croix-Rousse, 69317 Lyon 04, France. jean-yves.mabrut@chu-lyon.fr
Study Aim:
Study of clinical, diagnostic and therapeutic aspects of mesenteric and mesocolic cystic lymphangiomas.
Material And Methods:
15 cases were retrospectively analysed: 5 adults (mean age 36.8 years, range 26 to 46) and 10 children (mean age 23 months, range 0 to 5 years). Diagnosis was prenatal in 1 case. Symptoms were: abdominal pain (80%), fever (20%), abdominal mass (46%), occlusive syndrome (33%), chylous ascitis 1 case. Tumours were mesenteric (86%) or mesocolic (13%).
Results:
Complete resection was performed in 11 cases (including 10 bowel resections), incomplete resections in 3 and doxycycline sclerotherapy once. Mean follow-up is 5 years. One recurrence occurred 6 years after complete resection and 1 tumour increased after incomplete resection. Patient treated by sclerotherapy was non symptomatic with a 3.5 years follow-up after last injection.
Conclusion:
Mesenteric and mesocolic cystic lymphangiomas are congenital benign tumours. Complete resection should be performed whenever possible. Intracystic sclerotherapy with doxycyclin is possible for unresectable lymphangiomas.